Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 491 to 500 of 1090 total matches.
Implantable Cardioverter Defibrillators
The Medical Letter on Drugs and Therapeutics • Jan 26, 2009 (Issue 1304)
newsletter (Treatment Guidelines), a drug interactions database, handbooks, software, licenses ...
Implantable cardioverter defibrillators (ICDs) are widely used in patients at risk for sudden cardiac death (SCD) because these devices have been highly successful in terminating life-threatening ventricular arrhythmias and in increasing survival.
Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
in patients
with active malignancies.
DRUG INTERACTIONS — Daprodustat is primarily
metabolized by CYP2C8 ...
The FDA has approved daprodustat (Jesduvroq –
GSK), a hypoxia-inducible factor prolyl hydroxylase
inhibitor (HIF-PHI), for oral treatment of anemia due
to chronic kidney disease (CKD) in adults who have
been on dialysis for at least 4 months. It is the first
HIF-PHI and the first oral drug to be approved in the
US for this indication.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):25-7 doi:10.58347/tml.2024.1696a | Show Introduction Hide Introduction
Anidulafungin (Eraxis) for Candida Infections
The Medical Letter on Drugs and Therapeutics • May 22, 2006 (Issue 1235)
enzymes, and is not expected to have clinically
significant drug interactions. Metabolism of caspofungin ...
Anidulafungin (ay nid yoo la fun jin; Eraxis - Pfizer), a third intravenous echinocandin antifungal, has been approved by the FDA for treatment of esophageal candidiasis, candidemia, and other complicated Candida infections (intra-abdominal abscess or peritonitis).
MoviPrep: A New Bowel Prep for Colonoscopy
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007 (Issue 1262)
, DRUG INFORMATION: Jean-Marie Pflomm, Pharm.D.
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D ...
MoviPrep (Salix) is a new polyethylene glycol (PEG)-based bowel cleansing preparation approved for use in adults prior to colonoscopy. It contains ascorbic acid, which acts as an additional cathartic and flavoring agent, and requires a lower volume of fluid (3 L compared to the traditional 4 L) than most other PEG products. HalfLytely is an FDA-approved 2-L PEG product, but it must be taken with bisacodyl.
Natalizumab (Tysabri) for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • May 05, 2008 (Issue 1285)
of
18 months.
6
DRUG INTERACTIONS — Concomitant use of additional immunomodulators ...
Natalizumab (Tysabri - Elan and Biogen) is a monoclonal antibody approved for induction and maintenance treatment of moderate to severe Crohn's disease (CD) refractory to conventional therapies and inhibitors of tumor necrosis factor (TNF). Initially approved in 2004 for the treatment of multiple sclerosis (MS), natalizumab was temporarily withdrawn from the market after 3 patients developed progressive multifocal leukoencephalopathy (PML). It is now available for treatment of both MS and CD through a restricted distribution program.
Rezafungin (Rezzayo) for Invasive Candida Infections
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
infant or
milk production.
DRUG INTERACTIONS ― Rezafungin is not a
substrate, inhibitor, or inducer ...
The FDA has approved rezafungin (Rezzayo – Cidara/Melinta), an intravenous echinocandin antifungal, for
once-weekly treatment of candidemia and invasive
candidiasis (IC) in adults with limited or no alternative
options. It is the first new drug to become available
in the US in more than 15 years for treatment of
systemic Candida infections.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):101-4 doi:10.58347/tml.2024.1705d | Show Introduction Hide Introduction
Ixekizumab (Taltz) - A Second IL-17A Inhibitor for Psoriasis
The Medical Letter on Drugs and Therapeutics • May 09, 2016 (Issue 1494)
the
same as a carton containing a 150-mg dose (one 150-mg pen or syringe).
DRUG INTERACTIONS — No adverse ...
The FDA has approved ixekizumab (Taltz – Lilly), an
injectable humanized interleukin (IL)-17A antagonist,
for treatment of adults with moderate to severe plaque
psoriasis who are candidates for systemic therapy
or phototherapy. Ixekizumab is the second IL-17A
antagonist to be approved for this indication in the US;
secukinumab (Cosentyx – Novartis) was the first.
Osilodrostat (Isturisa) for Cushing's Disease
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
inhibits several
steps in cortisol synthesis, is relatively inexpensive,
but it interacts with many drugs ...
The FDA has approved osilodrostat (Isturisa –
Recordati), a cortisol synthesis inhibitor, for oral
treatment of adults with Cushing's disease when
surgical resection of the pituitary adenoma is not an
option or has not been curative. Osilodrostat is the
first cortisol synthesis inhibitor to be approved in
the US for this indication. Other oral steroidogenesis
inhibitors such as ketoconazole and metyrapone have
been used off-label for this indication for many years.
Valproate and Other Anticonvulsants For Psychiatric Disorders
The Medical Letter on Drugs and Therapeutics • Dec 11, 2000 (Issue 1094)
with
other drugs (Medical Letter Handbook of Adverse Drug Interactions, 2000, page 396).
CARBAMAZEPINE ...
Anticonvulsants are now widely used for treatment of psychiatric illnesses, particularly bipolar disorder. Lithium is the standard drug for treatment of bipolar disorder, but it can cause severe toxicity, serum concentrations must be monitored, and it is not effective in some patients.
Lamotrigine For Epilepsy
The Medical Letter on Drugs and Therapeutics • Mar 17, 1995 (Issue 944)
-life of a single dose is about 24 hours (KL Goa et al,
Drugs, 46:152, 1993).
DRUG INTERACTIONS ...
Lamotrigine (la mo tri jeen; Lamictal - Burroughs Wellcome), a phenyltriazine derivative, has been approved by the US Food and Drug Administration for use in addition to other antiepileptic drugs in adults with partial seizures. Since this diagnostic category includes the largest number of patients with intractable epilepsy, new drugs with antiepileptic activity are usually tried first for this indication. Lamotrigine was first marketed abroad in 1990 and is now available in more than 50 other countries.